Need Help With This Product?
Our specialists are here to help you find the best product for your application.
iCell GlutaNeurons, 01279
Products
Kits
- Cryopreserved iCell GlutaNeurons, 01279
- 2 ml Neural Supplement B
- 1 ml Nervous System Supplement
- User’s Guide
- Additional reagents required; see Quick/User’s Guide
genetic status
Quantity (Cells Per Vials)
Catalog #
Catalog #:
GlutaNeurons differentiated from human iPS cells, frozen
From
$716.00
Cells Only
- Cryopreserved iCell GlutaNeurons, 01279
- User’s Guide
- Additional reagents required; see Quick/User’s Guide
genetic status
Quantity (Cells Per Vials)
Catalog #
Catalog #:
GlutaNeurons differentiated from human iPS cells, frozen
From
$616.00
Product Overview
Understanding basic neuronal physiology and discovering therapeutics to treat neurological disorders has relied heavily on rodent primary cell cultures and animal models. These common systems have significant drawbacks in terms of biological relevance, reproducibility, and scalability. iCell® GlutaNeurons provide a relevant, excitatory neuronal model that enables researchers to study human neuronal network development and activity through interrogation and manipulation of relevant pathological pathways involved in seizurogenic and neurodegenerative conditions, thereby providing a new and valuable tool for drug discovery, toxicity testing, and basic research.
iCell GlutaNeurons, human glutamatergic-enriched cortical neurons derived from induced pluripotent stem (iPS) cells, display typical physiological characteristics and form functional neuronal networks amenable to examination across a number of commonly used assay techniques. These cells overcome limitations of existing models by providing the following:
- Fully differentiated, ≥90% pure population of primarily glutamatergic (excitatory) human neurons
- Long-term viability, demonstrated reproducibility, and availability in commercial quantities
- Rapid formation of excitatory neural networks and functional synapses
- Expression of relevant neurological therapeutic targets and pathways
- Compatible with a wide range of biochemical and cell-based assays including:
- Cell viability
- Calcium signaling
- Neurite outgrowth and retraction
- Electrophysiological applications:
- Identification and characterization of network function
- Higher throughput assessment of compound efficacy for seizure treatment
- Higher throughput detection of seizurogenic toxicity
- Ease of use; simply thaw and plate
Components:
Our regular business hours are 9:00am to 5:00pm Central Time (USA)
Need Help With This Product?
Our specialists are here to help you find the best product for your application.
Our regular business hours are 9:00am to 5:00pm Central Time (USA)
Technical Docs
PROTOCOLS
Application Protocols
Tri-Culture of iCell Microglia with iCell Neuronal Cell Types and iCell Astrocytes
USER DOCS
User's Guides
iCell GlutaNeurons
Datasheet
iCell GlutaNeurons
Biosafety Document
iCell GlutaNeurons Biosafety Document
Safety Data Sheet
iCell Neural Supplement B Safety Data Sheet
Safety Data Sheet
iCell Nervous System Supplement Safety Data Sheet
Safety Data Sheet
iCell Cell-Based Products Safety Data Sheet - Asia
Safety Data Sheet
iCell Cell-Based Products Safety Data Sheet
Safety Data Sheet
iCell Neural Base Medium 1 Safety Data Sheet
Performance Data
Expression of Synaptic and Glutamatergic Receptors in iCell GlutaNeurons.
Confocal immunofluorescent analysis of iCell GlutaNeurons at 7 days in vitro using Cell Signaling Technology antibodies. Top-left) Postsynaptic density protein PSD95 (green) co-stained for β3-Tubulin (red), and DAPI (blue). Top-right) Metabotropic glutamate receptor mGluR5 (D6E7B; green) co-stained with DAPI (blue). Bottom) AMPA receptor subunit GluA4 (green) co-stained for β3-Tubulin (red), and DAPI (blue). Staining performed and images kindly provided by Cell Signaling Technology.
Figure 2: iCell GlutaNeurons Provide a Highly Pure Population of Glutamatergic Cortical Neurons
Purity and Gene Expression Analysis of iCell GlutaNeurons
(A) The cells display typical morphology, developing branched networks within 24 hours. (B) Flow cytometry data verify a highly pure, fully differentiated neuronal population. (C) Immunofluorescent labeling identifies the synaptic marker synaptophysin, neuronal marker tuj-1, and nuclei. (D) Single-cell gene expression analysis confirms the high proportion of glutamatergic neurons, which enables the formation of synchronously bursting networks.
Neurotoxicity Assay
(A - D) Upon increased exposure to glutamate, iCell GlutaNeurons exhibit changes in their viability as assessed by, but not limited to, LDH release (CytoTox-ONE assay, Promega), reducing potential (RealTime-Glo assay, Promega), ATP presence (CellTiter-Glo assay, Promega), or membrane integrity (CyQUANT assay, Thermo Fisher Scientific), respectively. (E) Glutamate-induced cell death can be ameliorated by inhibition of NMDA (AP5) and AMPA (DNQX) receptors, as assessed by LDH release, highlighting the utility of iCell GlutaNeurons in screening for neuroprotectants
Figure 3: iCell GlutaNeurons Provide a Relevant Human-Derived Model for Investigating Neurotoxicity and Identifying Neuroprotectants
Product Highlights
Easy to implement
iCell GlutaNeurons are shipped cryopreserved with optimized media. Simply thaw and use.
Acute and long-term testing
iCell GlutaNeurons remain viable and pure in culture for more than 4 weeks, enabling assessment of synapse formation as well as network development and disruption.
Highly pure human cells
Terminally differentiated from human iPS cells, iCell GlutaNeurons provide a uniquely relevant biological model.
Homogenous and reproducible
Commercial quantities of consistent batches ensure reproducible large-scale screens and long-term projects.
Self-assembling networks
The capability to form predominantly excitatory neural networks provide a powerful tool in basic research and drug discovery studies.
Publications
Perfluorooctane Sulfonate (PFOS) and Perfluorooctanoate (PFOA) Acutely Affect Human α1β2γ2L GABAA Receptor and Spontaneous Neuronal Network Function in Vitro A Tukker, L Bouwman, R van Kleef, H Hendriks, J Legler, R Westerink. (2020) Sci. Rep. 10, 5311 (2020)
Towards Animal-Free Neurotoxicity Screening: Applicability of hiPSC-derived Neuronal Models for in Vitro Seizure Liability Assessment A Tukker, R van Kleef, F Wijnolts, A De Groot, R Westerink. (2020) ALTEX. 37(1):121-135. (2020)